Brokerages forecast that Edge Therapeutics, Inc. (NASDAQ:EDGE) will announce earnings per share (EPS) of ($0.48) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Edge Therapeutics’ earnings. Edge Therapeutics posted earnings of ($0.37) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 29.7%. The business is scheduled to announce its next quarterly earnings report on Tuesday, November 7th.

According to Zacks, analysts expect that Edge Therapeutics will report full year earnings of ($1.89) per share for the current year. For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.11) per share. Zacks’ earnings per share averages are an average based on a survey of research firms that follow Edge Therapeutics.

Edge Therapeutics (NASDAQ:EDGE) last issued its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.44).

Several research analysts have issued reports on the stock. Zacks Investment Research cut shares of Edge Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. BidaskClub upgraded shares of Edge Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday.

In other news, insider Brian A. Leuthner sold 7,500 shares of Edge Therapeutics stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $10.53, for a total value of $78,975.00. Following the completion of the sale, the insider now directly owns 125,236 shares in the company, valued at $1,318,735.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 36.19% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Regentatlantic Capital LLC acquired a new stake in shares of Edge Therapeutics during the first quarter valued at about $1,230,000. Eagle Asset Management Inc. raised its stake in shares of Edge Therapeutics by 4.4% in the first quarter. Eagle Asset Management Inc. now owns 899,968 shares of the biotechnology company’s stock valued at $8,198,000 after buying an additional 37,536 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Edge Therapeutics during the first quarter valued at about $297,000. TFS Capital LLC acquired a new stake in shares of Edge Therapeutics during the first quarter valued at about $209,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Edge Therapeutics during the second quarter valued at about $236,000. Institutional investors own 48.72% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/08/06/0-48-earnings-per-share-expected-for-edge-therapeutics-inc-edge-this-quarter.html.

Shares of Edge Therapeutics (EDGE) traded up 0.77% during midday trading on Friday, reaching $10.44. 20,971 shares of the company’s stock were exchanged. The firm has a 50-day moving average of $10.30 and a 200-day moving average of $9.79. The stock’s market capitalization is $321.85 million. Edge Therapeutics has a 12-month low of $7.30 and a 12-month high of $13.50.

About Edge Therapeutics

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Get a free copy of the Zacks research report on Edge Therapeutics (EDGE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Edge Therapeutics (NASDAQ:EDGE)

Receive News & Ratings for Edge Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.